Home / Market News / $COLL
benzinga Corporate Catalyst Impact 65/100 ● neutral

Collegium Pharmaceutical And Grünenthal Enter Settlement Agreement On Oct 15, 2026; Terminates Grünenthal License And Consent Agreement For Territory Effective Oct 15, 2026; Co. To Pay Grünenthal $17M In Settlement

Oct 19, 2026, 8:30 PM UTC · Primary ticker $COLL

Collegium Pharmaceutical has settled a patent infringement lawsuit with Grünenthal regarding its Nucynta products, agreeing to pay $17 million and terminate their existing license agreement. This resolves ongoing litigation and clarifies Collegium's future obligations regarding Nucynta royalties, potentially improving financial predictability.

Collegium Pharmaceutical has reached a settlement with Grünenthal, resolving a patent infringement lawsuit related to its Nucynta products. This agreement terminates the existing license and consent agreements, effectively ending Collegium's royalty obligations to Grünenthal for Nucynta in exchange for a one-time payment of $17 million. This is a positive development for Collegium as it removes the uncertainty and potential legal costs associated with the Nucynta Litigation, and eliminates ongoing royalty payments, which could improve future profitability. For traders, this removes a significant overhang, potentially leading to a short-term positive reaction as financial clarity is gained, and long-term benefits from reduced expenses.

$COLL positive Resolves patent litigation, eliminates future royalty payments
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.